Enanta Pharmaceuticals to Participate in Two Investor Conferences in September
09/01/2022 - 07:00 AM
WATERTOWN, Mass. --(BUSINESS WIRE)--
Enanta Pharmaceuticals, Inc. Jay R. Luly , Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September:
Wells Fargo Healthcare Conference : Presentation at 3:10 p.m. ET on September 8, 2022
Baird Global Healthcare Conference : Fireside Chat at 9:40 a.m. ET on September 13, 2022
A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com . Replays of the webcasts will be available following the presentations and will be archived for approximately 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S. ) and MAVIRET® (ex-U.S. ) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.
View source version on businesswire.com : https://www.businesswire.com/news/home/20220901005100/en/
Media and Investor Contact
Jennifer Viera
jviera@enanta.com
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals Inc
ENTA Rankings
#5339 Ranked by Stock Gains
ENTA Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Watertown
About ENTA
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
